Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Author Correction: Community benchmarking and evaluation of human unannotated microprotein detection by mass spectrometry based proteomics.

Nature communications·2026
Same author

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Expanding the human proteome with microproteins and peptideins.

Nature·2026
Same author

TCA cycle rewiring underpins histone acetylation sourcing and cell-fate transitions during exit from naive pluripotency.

Cell stem cell·2026
Same author

Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Erratum for the Research Article "Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer".

Science immunology·2026
Same journal

Langerhans cell control of early-life dermal lymphatic development shapes adult immunity.

Science immunology·2026
Same journal

T<sub>reg</sub> cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.

Science immunology·2026
Same journal

CXCL16-mediated recruitment of γδ T cells to the brain reduces sociability in mice.

Science immunology·2026
Same journal

Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.

Science immunology·2026
Same journal

Bacterial infection reshapes monocyte and macrophage ontogeny at the CNS borders.

Science immunology·2026
See all related articles

Related Experiment Video

Updated: Jul 24, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K

Restoring tumor immunogenicity with dendritic cell reprogramming.

Olga Zimmermannova1,2, Alexandra G Ferreira1,2,3,4, Ervin Ascic1,2

  • 1Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, BMC A12, 221 84 Lund, Sweden.

Science Immunology
|July 7, 2023
PubMed
Summary
This summary is machine-generated.

Reprogramming cancer cells into antigen-presenting cells (tumor-APCs) enhances immune recognition and antitumor responses. This novel immunotherapy approach, using transcription factors PU.1, IRF8, and BATF3, shows promise in delaying tumor growth and improving survival.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

Related Experiment Videos

Last Updated: Jul 24, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

9.9K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.9K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Reprogramming

Background:

  • Cancer cells evade immune detection partly due to decreased antigen presentation.
  • Dendritic cells are crucial for initiating adaptive immune responses against tumors.

Purpose of the Study:

  • To reprogram cancer cells into professional antigen-presenting cells (tumor-APCs).
  • To investigate the therapeutic potential of tumor-APCs in cancer immunotherapy.

Main Methods:

  • Utilized the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1).
  • Enforced expression of transcription factors PU.1, IRF8, and BATF3 (PIB) in 36 cancer cell lines.
  • Assessed transcriptional, epigenetic, and functional changes in reprogrammed tumor-APCs.

Main Results:

  • Reprogramming induced cDC1 phenotype, restoring antigen presentation complexes and costimulatory molecules.
  • Tumor-APCs enhanced endogenous antigen presentation on MHC-I, activating CD8+ T cells.
  • Reprogrammed cells showed impaired tumorigenicity, delayed tumor growth, and increased survival in vivo.
  • Tumor-APCs demonstrated synergistic effects with immune checkpoint inhibitors.

Conclusions:

  • Reprogramming cancer cells into tumor-APCs is a viable strategy to enhance anti-tumor immunity.
  • This approach offers a platform for developing novel immunotherapies targeting endogenous tumor antigens.
  • Tumor-APCs can be generated from both hematological and solid tumors, including primary human cells.